- Vienna '18
- Athens 2019
- ESCRS Player
- On Demand
- ESCRS iLearn
- ESCRS YO's
First Author: M.Alfayez SAUDI ARABIA
Back to previous
To prospectively evaluate the long-term safety and efficacy of collagen crosslinking for management of progressive keratoconus.
Institutional: The Eye and Laser Centre & King Abdulaziz University Hospital.
One hundred eighteen eyes of 89 patients with documented progressive mild to moderate keratoconus underwent corneal collagen cross-linking with riboflavin and UV-A, and followed up for a mean of 64 months (range 51-81 months). The primary measure was change in maximum K reading and secondary outcome was change in BCVA. Refraction, corneal thickness and endothelial cell count were also measured.
With a mean follow up of 64 months after cross-linking, maximum corneal curvature decreased by 2.4 D (P < .0001) and BCVA improved 1 or more lines in 62% of treated eyes (P < .05). No statistically significant difference in corneal thickness or endothelial cell density was found.
In this group of patients, long-term follow-up showed collagen crosslinking to be a safe and effective therapeutic option for progressive keratoconus.